November 30, 2012
BioCryst (Nasdaq: BCRX ) announced today that it is canceling its merger with Presidio Pharmaceuticals, an event that Motley Fool health care analyst Brenton Flynn predicted could happen last month. With BioCryst's Hep-C candidate impaired, and companies like Abbott (NYSE: ABT ) and Gilead (NYSE: GILD ) already light-years ahead in the race for an all-oral Hepatitis C regimen, it's easy to understand why a deal for Presidio and its phase-2-ready drug didn't make sense.
With the impending spinoff of its branded-drug business, Abbott Labs is losing a massive blockbuster drug in Humira. It's a confusing event to understand, with many investors left wondering what to do with these two stocks once they're separated. To help investors better understand the upcoming event, the Fool has created a brand new premium report outlining both Abbott Labs and its spinoff, AbbVie. Inside, we outline all of the must-know opportunities and risks facing both companies, so make sure to claim this 2-for-1 report by clicking here now.